Ones To Watch News
Refine Search
Biotechnology
Shares of US neurodegenerative diseases focussed biotech firm Denali Therapeutics slumped 13% to $33.53 by late afternoon yesterday, after the company revealed it was informed via e-mail communication from the US Food and Drug Administration that the Investigational New Drug (IND) application for its Alzheimer’s disease candidate DNL919 (ATV:TREM2) has been placed on clinical hold. 14 January 2022
Biotechnology
Danish biotech Ascendis Pharma saw its shares edge up more than 3% to $125.79 today, after it announced that the European Commission (EC) has granted marketing authorization for Lonapegsomatropin Ascendis Pharma (developed under the name TransCon hGH). 13 January 2022
Biotechnology
AstraZeneca has signed a collaboration agreement with Boston, USA-based next-generation oncology company Scorpion Therapeutics to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment, the UK pharma major announced today. 13 January 2022
Biotechnology
Chinese biotech Hutchmed today announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy designation (BTD) to HMPL-523, a novel, investigational spleen tyrosine kinase (Syk) inhibitor, for the treatment of chronic adult primary immune thrombocytopenia (ITP) patients who have received at least one prior therapy. 12 January 2022
Biotechnology
UK blood diseases specialist Hemogenyx Pharmaceuticals and Swiss biotech Selexis, a JSR Life Sciences company, have signed a service agreement to develop the cell line for the company's CDX bispecific antibody for the treatment of acute myeloid leukemia (AML). 12 January 2022
Biotechnology
US clinical stage cell and gene therapy company Castle Creek Biosciences says it has acquired Novavita Thera, a pre-clinical gene therapy company focused on rare liver and metabolic diseases. 11 January 2022
Biotechnology
Japan’s largest drugmaker Takeda Pharmaceutical announced the exercise of its option to acquire Adaptate Biotherapeutics, a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells. 10 January 2022
Biotechnology
Shares of Century Therapeutics shot up 15.1% to $15.22, after it revealed a research collaboration and license agreement with pharma major Bristol Myers Squibb to develop and commercialize up to four induced pluripotent stem cell (iPSC) derived, engineered natural killer cell (iNK) and0/or T cell (iT) programs for hematologic malignancies and solid tumors. 10 January 2022
Biotechnology
UK antibody drug conjugate (ADC) company Iksuda Therapeutics (Iksuda) today announced further expansion of its differentiated ADC pipeline through a license and commercialization agreement with South Korea-based LegoChem Biosciences (LCB). 10 January 2022
Biotechnology
A collaboration between one of the world’s largest drug companies, Pfizer, and a young precision medicine company called Beam Therapeutics, will explore the potential for a new technique in precision medicine. 10 January 2022
Biotechnology
Pharma giant Novartis and Swiss clinical-stage biotech Molecular Partners today announced that Part A of the EMPATHY clinical trial that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate versus placebo to treat COVID-19, met the primary endpoint of viral load reduction over eight days. 10 January 2022
Biotechnology
Alexion, the rare diseases unit of Anglo-Swedish pharma major AstraZeneca (LSE: AZN), has entered into an exclusive global collaboration and license agreement with Swiss immunotherapy firm Neurimmune for NI006. 7 January 2022
Biotechnology
RNAi therapeutics company Alnylam Pharmaceuticals closed down 2.6% at $151.00 yesterday, after it revealed it has entered a collaboration with Swiss pharma giant Novartis. 7 January 2022
Biotechnology
Eikon Therapeutics, a pioneer in the application of live-cell super-resolution microscopy to drug discovery, has closed a $517.8 million Series B financing. 7 January 2022
Biotechnology
Belgium-based biotech Univercells today announced its acquisition of SynHelix, a French biotechnology company. 6 January 2022
Biotechnology
Shares in Californian autoimmune specialist Annexon slumped over 40% on Wednesday, after the firm announced interim Phase II data for its Huntington’s disease candidate ANX005. 6 January 2022
Biotechnology
Terms for a research and licensing collaboration between CRISPR company Intellia Therapeutics and privately-held cell therapy firm Kyverna Therapeutics have been agreed. 6 January 2022
Biotechnology
PhoreMost, a UK-based biopharma dedicated to developing drugs against intractable disease targets, has announced a collaboration to study oncology targets currently considered ‘undruggable’ with Polaris Quantum Biotech (POLARISqb), a North Carolina, USA-based quantum computing drug design company. 5 January 2022
Biotechnology
USA-based Genocea Biosciences has entered into an R&D collaboration and option agreement with Janssen Biotech, part of US healthcare giant Johnson & Johnson, to explore the immunogenicity of neoantigens and the role and impact of Inhibigens in the context of vaccine therapies for cancer. 5 January 2022
Biotechnology
Denmark’s Genmab and privately-held Dutch biotech Synaffix have signed a license agreement providing Genmab broad access to Synaffix’ ADC technologies. 4 January 2022
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze